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In an editorial on our paper dealing with diet and its relation to coronary heart disease (CHD) and death,1 Scott et al. 2 addressed some general statistical issues.
The initial tables in our paper compared the means of various nutrients for CHD cases and noncases. The editorial describes circumstances in which such a comparison will mislead us. We would go further than the editorial. It is, in fact, conceptually imprecise to consider cases and noncases arising from a set of prospective observations as constituting two separate populations. They arise from one population and should be so treated.8 ' Thus, we are not persuaded that the statistical issue warrants the concerns expressed in the extended consideration in the editorial of the two-population model. On the other hand, at the practical level, the t test for mean differences usually yields conclusions consistent with those from a more exact analysis.' In the analysis of large bodies of data it has the advantage of being cheaper and less time-consuming than a logistic analysis. This is particularly attractive when a large number of variables must be considered. However, when an examination of the mean differences suggested a potentially significant association, we confirmed it with a logistic analysis, as the editorial noted.
Uniformly, the conclusions were the same by both methods.
It is true that the logistic function assumes monotonicity of risk over the independent variables." As was noted in the editorial, sample data for the key diet variables were presented in our paper. The trends were "not easily discernible," but nothing about the data would suggest we reject the assumption of monotonicity. However, the possibility does exist that some diet variables found to have insignificant relations when examined by our methods are, in fact, related to the incidence of coronary heart disease or death. Beyond these statistical issues, however, it must be conceded that in some instances the biologic facts may be more complicated. Thus, it is possible that persons consuming large quantities of alcohol on a regular basis may be at greater risk of developing coronary heart disease than moderate drinkers, as one study suggests.' Our data do not indicate that to be the case for our populations; hence we had no reason to allow for that in our model.
Multiple comparisons can affect the probability estimates. However, we emphasized not individual test results, but the replication of results; that is, the concordance of results from three separate studies. And what we are concerned with now is in finding out whether other studies confirm or help to explain our findings. demonstrated that naloxone administration before sleep prevented the decrease in systolic pressure that is normally seen during the second cycle of deep sleep. This effect of naloxone was delayed, becoming manifest more than 140 minutes after drug infusion. The mechanism of naloxone's action on the blood pressure may be mediated through naloxone-induced release of endogenous vasopressin.
Both apomorphine and naloxone block the morphine-induced increases in serum prolactin,' and the time course of effect of naloxone on preventing the blood pressure decrease during sleep coincides with its effect on prolactin release, maximal at 180 minutes.8 Apomorphine is a potent dopamine-receptor stimulant, and some of the morphine withdrawal signs have been linked to an increased stimulation of dopamine receptors.4 Rowe et The finding that naloxone's hypertensive effect is delayed by more than 2 hours suggests that the control it exerts on blood pressure is indirect. Plasma vasopressin has been demonstrated to be responsible for long-term blood pressure maintenance in rat and dog.' Apomorphine induces vasopressin release and its action can be blocked by haloperidol, which also blocks naloxone-induced withdrawal reaction, and so, possibly, naloxone's delayed hypertensive effect may be mediated through vasopressin release. Although Lightman et al. proposed that naloxone may block or exert no effect on vasopressin release,0' 11 it is noteworthy that in these two studies, nal'oxone was used at very low doses (0.08-0.12 mg/min) administered by slow infusion over a protracted period (40-120 minutes), and was not associated with a delayed hypertensive effect. In contrast, the studies demonstrating a delayed effect on blood pressure and elevation in plasma vasopressin used much larger doses (14-20 mg), administered in bolus form.1 8 Because some signs of opioid withdrawal have been attributed to an increase, and others a decrease, in dopaminergic activity,6 naloxone's effect
